Small-cap stock soars 76% in 1 year; Motilal Oswal sees 26% more upside— a potential multibagger in the making?
Small-cap stock: Blue Jet Healthcare share price jumped over 6 per cent in intraday trade on the BSE on Wednesday, April 30, looking set to snap its three-day losing run after domestic brokerage firm Motilal Oswal Financial Services initiated coverage on the stock with a buy recommendation, suggesting the potential for multibagger returns. The small-cap stock opened at ₹ 690 against its previous close of ₹ 686.70 and rose over 6 per cent to an intraday high of ₹ 729.25. Around 11 AM, Blue Jet Healthcare share price traded 5.61 per cent higher at ₹ 725.20. Equity benchmark Sensex was flat at 80,293 at that time.
Blue Jet Healthcare share price has been on a roll over the last year, surging 76 per cent as of April 29 close.
Shares of Blue Jet Healthcare debuted on the Indian stock exchanges on November 1, 2023. In just about a year and a half, the stock has rallied 98.5 per cent from its issue price of ₹ 346. Based on today's high of ₹ 729.25, it has more than doubled investors' money, delivering multibagger returns of 111 per cent.
The small-cap stock recently hit its 52-week high of ₹ 968.75 on March 21 this year, whereas it hit a 52-week low of ₹ 346.70 on June 4 last year.
However, it has seen selling pressure in April. As of the previous session's close, the stock has suffered a loss of 22 per cent this month and is set to snap its five-month winning streak.
Despite stellar gains over the last year, domestic brokerage firm Motilal Oswal Financial Services believes the stock has more room to grow.
The brokerage firm has initiated coverage on the stock with a 'buy' recommendation. Motilal has given a target price of ₹ 865, implying a 26 per cent upside potential from the stock's April 29 close.
"With its niche product offerings in contrast media and pharmaceutical intermediaries and API (active pharmaceutical ingredient), Blue Jet Healthcare has been changing how the healthcare industry caters to the therapeutic needs of patients around the globe," Motilal Oswal noted.
"The company has established itself as a reliable supplier to its customers for the past three decades and is now working toward moving up the value chain by significantly increasing its investment in R&D (research and development)," the brokerage firm added.
Motilal said Blue Jet Healthcare's revenue growth will be driven by new products in iodinated and gadolinium contrast media, NCE intermediates, and a high-intensity sweetener variant.
The brokerage firm also said the PI/API segment is set for strong growth, with a ramp-up in supplies for Esperion's Bempedoic acid in the coming quarters.
Taking note of the existing products ramping up and new product launches, Motilal Oswal expects Blue Jet Healthcare to post a CAGR of nearly 27 per cent, 24 per cent and 19 per cent in revenues, EBITDA and PAT, respectively, over FY25-27E.
Motilal also expects a sharp uptick in the pharma Intermediaries segment, and an average EBITDAM of 35.1 per cent during FY25-27E.
On the valuation front, according to Motilal Oswal, the stock is trading at a PE (price-to-earnings) of nearly 28 times on FY27E EPS (earnings per share) of ₹ 24.7 and FY27E EV/ EBITDA (enterprise value to earnings before interest, taxes, depreciation and amortisation) of nearly 20 times.
Read all market-related news here
Read more stories by Nishant Kumar
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
22 minutes ago
- Mint
Buy or sell: Vaishali Parekh recommends three stocks to buy today — 12 June 2025
Buy or sell stocks: The Indian stock market continued to trade volatile for the sixth straight session on Wednesday. The Nifty 50 index ended higher for the sixth straight session and finished at 25,141. The BSE Sensex gained 123 points and closed at 82,515, while the Bank Nifty index went off 169 points and closed at 56,459. Sectorally, oil & gas, IT, and pharma were the major gainers, demonstrating strength even in a consolidating market. However, Nifty PSU Banks, FMCG, and metal sectors ended the day in the red. In a change from recent trends, the Nifty Mid-cap and Small-cap indices broke their winning streak today. The Nifty Mid-cap 100 Index fell by 0.49%, while the Nifty Small-cap 100 Index went down by 0.53%. However, market breadth remained decisively positive, with advancing stocks significantly outpacing declining ones, as indicated by a BSE advance-decline ratio of 1.24. Vaishali Parekh, Vice President of Technical Research at Prabhudas Lilladher, believes the Indian stock market bias has turned slightly cautious as the Nifty 50 index slipped after hitting 25,200 levels. However, the key benchmark index has closed above 25,116, meaning the positive sentiment remains intact. The Prabhudas Lilladher expert said the 50-stock index is facing a hurdle at 25,200, and the index may soon touch 25,600 after breaking above 25,200 on a closing basis. Speaking on the outlook of the Nifty 50 today, Vaishali Parekh said, "The Nifty 50 index, after consolidating since the last two days, witnessed a volatile session with the initial half progressed ahead to scale the 25,200 zones while post-lunch session succumbed to profit booking to end near the 25,150 level with sentiment slightly turning cautious. The index has the 25,000 zones as the near-term support, while on the upside, the 25,500 level can be expected in the coming sessions once there is a breach above the hurdle of 25,200 levels, with overall bias maintained strong." "The Bank Nifty index has witnessed another session of profit booking to slip further from the peak made near the 57,000 zone, and with the 55,800 to 56,000 band maintained as the important support from the current level, the index is still in the strong territory but would need a decisive breach above the 57,000 level to anticipate for fresh upward move in the coming days to maintain the positive bias intact," said Parekh. Parekh said that today, support for the Nifty is at 25000 levels, while resistance is at 25,300. The Bank Nifty will have a daily range of 56,000 to 57,200. Regarding stocks to buy today, Vaishali Parekh recommended these three buy or sell stocks: Lloyds Enterprises, Lupin, and Natco Pharma. 1] Lloyds Enterprises: Buy at ₹ 73, Target ₹ 83, Stop Loss ₹ 70; 2] Lupin: Buy at ₹ 2028, Target ₹ 2150, Stop Loss ₹ 1980; and 3] Natco Pharma: Buy at ₹ 935, Target ₹ 1000, Stop Loss ₹ 900. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
New Indian Express
23 minutes ago
- New Indian Express
India hopes for trade fair and square with US
NEW DELHI: Even as India is racing against time to clinch a trade deal with the US before expiry of the July 9 deadline, when the 90-day exemption period for implementation of reciprocal tariff gets over, sources say that the first phase of the deal would only address the low-hanging fruits. 'The trade talks will be in multiple phases, but the first phase should end before July 9,' said an anonymous government source. With US president Donald Trump announcing a deal with China on Wednesday, India would be in a hurry to conclude the first phase before July 9. The US has also finalized a trade deal with the UK. India was the first country to start negotiating a trade deal with the US. In an interview with French newspaper Le Figaro on Tuesday, Foreign Minister S Jaishankar had said he is hopeful of reaching an agreement with US before the reciprocal tariffs kick in. A US delegation which visited India had a four-day meeting with Indian negotiators. The meeting ended on Tuesday. The talks veered from tariff rates, better market access, digital trade, and tariff on agriculture and allied goods. The two teams reportedly discussed the issue of a 50% tariff on steel and aluminium. India has threatened retaliatory action against the US over doubling tariffs on steel and aluminium.
Mint
37 minutes ago
- Mint
Will the China-US truce spell rare-earth relief?
Gift this article After two days of hectic talks in London between trade representatives of the US and China, another trade truce has been declared struck, with the two countries agreeing to fully implement the last one forged in Geneva. Under it, they had agreed to a suspension of new tariffs. After two days of hectic talks in London between trade representatives of the US and China, another trade truce has been declared struck, with the two countries agreeing to fully implement the last one forged in Geneva. Under it, they had agreed to a suspension of new tariffs. Also Read: China risks overplaying its hand by curbing rare earth exports The US had apparently expected Beijing to ease its export curbs on rare earth minerals, a severe shortage of which has lately sent key industries—from defence to electronics and electric vehicles (EVs)—into a tizzy across the world. Instead of ending export barriers, Beijing may have taken its part of the bargain to mean faster shipment clearances. The London outcome seems to offer America Inc relief, as US commerce secretary Howard Lutnick has said the US expects the squeeze to be resolved now. The framework deal only awaits the leaders of both countries to sign off on it. It's unclear, however, whether this can be greeted as good news by non-US importers of those rare earths. EV-makers in India have also faced a rare-earth crunch that threatens to hold EV production back. Beijing has been dragging its feet on okaying supplies to Indian importers. Maybe India needs to hold talks with China too. Topics You May Be Interested In
